BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 09:29 (652 d 04:57 ago) – Posting: # 20530
Views: 1,201

Hello again!

Today I have to read this here:

https://www.fdanews.com/articles/192544-persion-petitions-fda-to-raise-the-safety-bar-for-extended-release-opioid

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
21,518 posts in 4,498 threads, 1,523 registered users;
online 6 (0 registered, 6 guests [including 4 identified bots]).
Forum time: Saturday 14:26 CEST (Europe/Vienna)

If I find 10,000 ways something won’t work, I haven’t failed.
I am not discouraged, because every wrong attempt discarded
is another step forward.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5